Breakthrough First-in-Class Covalent Werner Helicase Inhibitor Demonstrates Clinical Proof-of-Concept in Phase I Trial
In a landmark development in the field of oncology and targeted cancer therapies, researchers at The University of Texas MD Anderson Cancer Center have unveiled...